Mortality Clinical Trial
Official title:
Azithromycine Pour la Vie Des Enfants au Niger II
Several randomized controlled trials have demonstrated that azithromycin mass drug administration (MDA) reduces child mortality, but increases antimicrobial resistance (AMR). The World Health Organization (WHO) guidelines for this intervention specify that implementation must be accompanied by continued monitoring of mortality and AMR. Niger is expanding the azithromycin MDA program nationwide. To establish monitoring of mortality and AMR as part of this program as well as to leverage the infrastructure to evaluate other child health interventions, AVENIR II is designed as an adaptive platform trial with monitoring and re-randomization every 2 years.
AVENIR II is a cluster-randomized adaptive platform trial designed to evaluate community health interventions in Niger. The initial focus is to monitor under-5 mortality and antimicrobial resistance as the azithromycin MDA for child survival program expands in Niger, with the following specific aims: 1. Mortality. 1. To conduct surveillance of mortality over time compared to the Sustainable Development Goal targets for under-5 mortality reduction. As this intervention is not intended to continue indefinitely, surveillance against a target is needed to determine when to stop. 2. To continue to evaluate the effectiveness of azithromycin MDA to reduce under-5 mortality. Given the risk of AMR, the effectiveness of the intervention over time is needed to fully weigh the risks against the benefits. 2. Antimicrobial Resistance. To determine the impact of azithromycin MDA on AMR in population- and clinic-based samples. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
| Completed |
NCT04092465 -
Outcomes of Surgical Resection After Induction Treatment in Non-Small Cell Lung Cancer (SRaIT)
|
||
| Completed |
NCT03296423 -
Bacillus Calmette-guérin Vaccination to Prevent Infections of the Elderly
|
Phase 4 | |
| Not yet recruiting |
NCT04900610 -
The Effect of Vitamin K2 Supplementation on Arterial Stifness and Cardiovascular Events in PEritonial DIAlysis
|
N/A | |
| Completed |
NCT04149873 -
Effectness of Treatment With Mechanical Insufflation-Exsufflation
|
N/A | |
| Completed |
NCT05905042 -
Follow-up of Recovery Condition in Survivors of Acute Respiratory Distress Syndrome
|
||
| Completed |
NCT00527774 -
Effect of HCV Infection on Insulin Resistance and Malnutrition-inflammation Complex Syndrome in Regular Hemodialysis Patients
|
N/A | |
| Completed |
NCT00518856 -
Lufwanyama Neonatal Survival Project
|
N/A | |
| Completed |
NCT06408636 -
Prognostic Role of LA Strain in Acute Myocardial Infarction
|
||
| Completed |
NCT06051526 -
The African Critical Illness Outcomes Study
|
||
| Recruiting |
NCT05055089 -
Short- and Medium-term Results of New Generation Aortic
|
||
| Active, not recruiting |
NCT04132492 -
AGNES - Aging Nephropathy Study, a Prospective Observational Cohort of Chronic Kidney Disease in Elderly Patients
|
||
| Completed |
NCT03885206 -
Effectiveness and Clinical Outcomes of Municipal Acute Wards Versus a General Hospital
|
N/A | |
| Completed |
NCT05573659 -
Capillary Refill Time Calculated With a Video-assisted Method Has a Better Reproducibility Than Visual Method in Critically Ill Patients
|
N/A | |
| Withdrawn |
NCT03245658 -
The Effect of Cannabis in Pancreatic Cancer
|
Phase 2 | |
| Recruiting |
NCT04094428 -
Burden, Mortality and Supply Costs in Intensive Care Unit Patients
|
||
| Completed |
NCT01631799 -
Outcome of Patients After Total Knee Replacement: A Comparison of Femoral Nerve Block and Epidural Anesthesia
|
N/A | |
| Completed |
NCT00244673 -
Randomized Study of Not Giving Diphteria-tetanus-pertussis Vaccination With or After Measles Vaccination
|
Phase 4 | |
| Completed |
NCT03378843 -
Spermidine Intake and All-cause Mortality
|
N/A | |
| Recruiting |
NCT04424511 -
Effects of Mass Drug Administration of Azithromycin on Mortality and Other Outcomes Among 1-11 Month Old Infants in Mali
|
Phase 3 |